Until the introduction of tyrosine kinase inhibitors, only limited treatment options were available for advanced/inoperable gastrointestinal stromal tumours (GISTs), the most common mesenchymal tumours of the gastrointestinal tract. Initially, it was imatinib mesylate that revolutionised patient outcomes in advanced cases, followed by sunitinib malate when the activity of imatinib turned out to be time-limited. There is substantial heterogeneity between GISTs in terms of response to targeted therapy. As was the case for imatinib, the efficacy of sunitinib depends on the primary tumour's KIT/PDGFRA (platelet-derived growth factor receptor-alpha) genotype and on secondary mutations emerging during treatment. Interestingly, sunitinib-related adverse effects, such as arterial hypertension, may serve as biomarkers of the antitumour efficacy of the drug. Here we discuss possible mechanisms underlying these phenomena as well as data from our recently published study -the first to investigate the clinicopathologic and genetic characteristics associated with the results of sunitinib therapy in a large group of patients treated in routine clinical practice.
Gastrointestinal stromal tumours (GISTs) are rare mesenchymal tumours that may develop anywhere along the gastrointestinal tract.
Approximately 95 % of cases share the expression of the CD117 surface antigen, also known as KIT or stem cell factor receptor. The management of localised GISTs relies on the complete surgical excision of the tumour. Until the introduction of tyrosine kinase inhibitors (TKIs), limited treatment options were available for patients once the tumour had spread or if it was inoperable. 1 Unprecedented improvement in the management of advanced GIST has been achieved through the relatively recent recognition of the important biological role of activating mutations in the KIT and PDGFRA (platelet-derived growth factor receptor-alpha) genes. These observations led to the introduction into therapy of imatinib mesylate, a small-molecule selective TKI targeting stem-cell factor receptor (KIT, CD117), breakpoint cluster region/C-abl oncogene 1, non-receptor tyrosine kinase (BCR/ABL) and platelet-derived growth factor receptors (PDGFRs) A and B. Imatinib revolutionised the treatment of patients with advanced CD117-positive GISTs and is currently approved as first-line treatment in metastatic and/or inoperable disease. [2] [3] [4] [5] [6] However, approximately 10-15 % of GIST patients are initially insensitive to imatinib, around 5 % are intolerant to it, and the spectacular response of the remaining patients is time-limited. As shown by median progression-free survival (PFS), approximately 50 % of patients treated with imatinib ultimately develop secondary resistance and experience disease progression within two years of treatment initiation.
2,3,5
The management of GIST resistant to first-line treatment represents a clinical challenge. 5 Insights into resistance mechanisms have allowed the development of several alternative strategies for patients who experience disease progression following imatinib treatment, which are currently being tested. In the case of generalised disease progression (or intolerance to imatinib), monotherapy with an alternative multitargeted TKI -i.e., sunitinib -represents the main option. Sunitinib remains the only approved second-line drug for the treatment of advanced GIST after failure of imatinib therapy.
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Sunitinib
Sunitinib malate is a multitargeted agent, as it has been proven to be active against a broad spectrum of tyrosine kinases: KIT, PDGFRA/B, vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3, FMS-like tyrosine kinase 3 (FLT-3), colony stimulating factor 1 receptor (CSF1-R), RET proto-oncogene and, to a lesser extent, fibroblast growth factor receptor 1 (FGFR-1). • PFS was four times as long with sunitinib than with placebo (24.1 versus 6.0 weeks; HR 0.33; p<0.0001);
• the most common treatment-related adverse events (AEs)
were fatigue, diarrhoea, skin discoloration and nausea; they were usually grade 1/2 and easily managed; serious treatment-related AEs were reported in 40 (20 %) and five (5 %) patients in the sunitinib and placebo groups, respectively; and
• dose reductions were needed in 23 (11 %) patients receiving sunitinib on a six-week cycle schedule, but not in any patients receiving placebo.
A study performed in our institution constitutes one of the largest series of GIST cases after imatinib failure (137 patients) analysed for the outcome of sunitinib treatment in routine practice, outside randomised, controlled clinical trials. 17 Our aim was to evaluate factors predicting outcome and toxicity of sunitinib second-line therapy in inoperable/metastatic GIST after failure of imatinib therapy.
We confirmed that many advanced GIST patients benefit from sunitinib therapy -mainly due to stabilisation of disease according to RECIST (response evaluation criteria in solid tumors), but not Choi criteria 18 -with overall survival (OS) exceeding 1.5 years. The median PFS of longer than seven months is almost equal to the results obtained in the Korean single-centre study.
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Adverse Events Related to Sunitinib Treatment
Sunitinib therapy is associated with several AEs, which are generally mild-to-moderate. As a dose-response relationship has been observed, 20 only otherwise intolerable side effects should be managed by dose modulation (including continuous administration of a lower dose). 7, 19, 21, 22 Most of the side effects increase in intensity as the cycle progresses, but then begin to resolve during the two-week break, providing the rationale for the six-week cycle administration schedule described above.
The most common AEs related to sunitinib treatment are fatigue, diarrhoea, skin discoloration, nausea, mucositis, arterial hypertension, hand-foot syndrome, myelosupression, impairment of left ventricular ejection fraction and hypothyroidism. 15, 16 Hypothyroidism was not originally highlighted among AEs in clinical trials of sunitinib and the basis of its development is not completely understood. Outside clinical trials, its occurrence has been reported in up to 46 % of GIST patients (30 % in our study). 17, 23, 24 More frequently observed in renal cell carcinoma (RCC) than in GIST patients, it may be influenced by previous cytokine treatment.
In vitro studies suggest inhibition of thyroid peroxidase activity, 25 degeneration of thyroid follicular cells 26 and reduction in vascularity 27 as possible explanations. One study reported a more than doubled median duration of sunitinib treatment in patients developing hypothyroidism, compared with patients not developing thyroid function abnormality (48 versus 21 weeks), but it made no further comments on the issue. 24 Studies performed in a group of RCC patients did not support any hypothyroidism-driven sunitinib therapy advantage. 28 The sunitinib toxicity profile observed in our study is similar to that observed in clinical trials (see Table 1 ), with the already mentioned exception of hypothyroidism. However, up to one-third of the cases in our study were classified as experiencing severe toxicity (and two deaths due to tumour haemorrhage were classified as related to sunitinib therapy). Our experience with patients with unresectable or metastatic GIST treated with TKIs suggests a higher incidence of emergency operations for gastrointestinal bleeding, bowel obstruction or abscess occurring during second-line therapy with sunitinib, compared with first-line therapy with imatinib. 29, 30 This increased incidence of surgical complications with sunitinib could be associated with the presence of more advanced and drug-resistant disease, or it could be the direct result of the mechanism of action of sunitinib -i.e., the combination of cytotoxic and antiangiogenic activity -leading to dramatic tumour response.
Mutational Status of KIT/PDGFRA Genes in Gastrointestinal Stromal Tumours
Several studies have confirmed that activating mutations of KIT/PDGFRA genes, which can be detected in around 85 % of primary GISTs, influence dosage and general efficacy of TKI treatment. [31] [32] [33] Non-random mutation distribution has been observed, relating to functional domains of the tyrosine kinase (TK) receptor. Mutations have been detected in exon 9
(extracellular/dimerisation domain), exon 11 (juxtamembrane domain), exons 13/14 (which encode the drug/ATP binding pocket
Gastrointestinal Cancer what is seen with imatinib, tumours initially (i.e., pre-sunitinib treatment) bearing KIT exon 9 mutations have a higher chance to respond to sunitinib than those with primary KIT exon 11 mutations (however, we have also observed some objective responses in the latter patient group). 17, 36 The clinical benefit of sunitinib in wild-type (WT) cases is also clear (see Figure 1) . We did not observe any response to sunitinib in the PDGFRA mutation (p.D842V predominantly)
group, an observation also made when looking at preclinical data. 37 In a Phase I/II trial of sunitinib conducted in GIST patients with imatinib-resistant tumours, the rate of partial responses was significantly higher in patients with primary KIT exon 9 mutations than in those with exon 11 mutations (37 % versus 5 %). Additionally, patients with KIT exon 9 mutations or WT KIT had a four times longer PFS and doubled OS compared with patients with exon 11 mutations. 36 In vivo testing for secondary mutations, if performed, reveals them as the reason for resistance to sunitinib in at least 50 % of patients (more than 80 % if a resistant clonal nodule develops within a pre-existing tumour mass). 38, 39 In vitro, sunitinib activity against KIT double mutants depends on the location of the secondary mutation, that always occurs in the cis configuration (the same allele). 40 Secondary mutations have been detected mainly in patients who were initially found to have primary KIT mutations and rarely in those with primary PDGFRA mutations. 41 Distribution of secondary mutations is non-random and they cluster either in the first or second TK domain of KIT. These mutations are significantly more common in GISTs with primary KIT exon 11 mutations, since they were found in 73-86 % of imatinib-resistant patients harbouring exon 11 primary mutations and only in 19-33 % of patients with the exon 9 primary mutation. 34, 35 Among all patients with secondary KIT mutations, the median PFS and OS with sunitinib was significantly longer for the patients harbouring KIT exon 13/14 mutations than exon 17/18 mutations, 36 an observation that has been confirmed by in vitro studies showing that sunitinib is not active against most imatinib-resistant secondary mutations involving the KIT activation loop. 37 As a substantial part of secondary mutations are located in the kinase activation loop, the phenomenon may be responsible for the more favourable outcome of patients with exon 9 mutations. 42 Although potentially informative, the analysis of secondary mutations is very challenging, and assessing the type of secondary mutation may have little utility in the prediction of sunitinib efficacy in routine practice, because imatinib-resistant GISTs are genetically very heterogeneous. Several teams have shown that, in most cases, the evolution of imatinib resistance is polyclonal -i.e., different lesions may have different secondary mutations and single lesions may contain more than one imatinib-resistant clone. 39, 43, 44 In routine practice, our therapeutic decisions are based on the primary GIST genotype.
Arterial Hypertension and Pharmacogenetics of Sunitinib
Arterial hypertension is a frequent side effect associated with inhibition of the vascular endothelial growth factor (VEGF) pathway;
it has been observed in 20-30 % of patients treated with bevacizumab (VEGF-A blocking antibody) and 15-60 % of patients treated with various VEGFR kinase inhibitors, including sunitinib. 45 Arterial hypertension usually occurs early after treatment initiation. Hypothetical mechanisms leading to arterial hypertension related to sunitinib have been proposed, including the presence of less perfused microvessels and/or a diminished number of microvessels, 47 decreasing nitric oxide production 48 and activation of the endothelin 1 pathway leading to vasoconstriction. 49 It has been recently postulated that sunitinib-induced arterial hypertension may serve as a biomarker of antitumour efficacy. It was first reported as a predictive factor of antitumour efficacy in metastatic RCC patients -a correlation that has been extensively studied. [50] [51] [52] [53] [54] [55] Treatment-induced persistent hypertension was associated with frequent tumour response, an extended time to disease progression and longer OS. 55 Clinical outcomes were not compromised by treatment with antihypertensive medication; moreover, patients who required at least three antihypertensive drugs had the longest PFS and OS. 54 The mechanism seems to be universal, as the clinical benefit seen alongside TKI-induced arterial hypertension in RCC was independent of inhibitor (sunitinib, sorafenib or bevacizumab) and line of treatment. 56 The most comprehensive study published until now regarding sunitinib-induced hypertension as a biomarker of treatment efficacy in metastatic RCC has been provided by Rini et al. 51 on the basis of a retrospective analysis of efficacy (n=544) and safety (n=4,917) in four studies that used the standard sunitinib six-week cycle schedule (four weeks of treatment followed by a two-week break). Patients who experienced sunitinib-induced arterial hypertension had better outcomes (objective response rate six times greater, OS more than four times longer) than those who did not, while the safety of treatment was not compromised (i.e., patients with sunitinib-induced arterial hypertension did not experience more AEs, apart from arterial hypertension, than other patients). In a multivariate analysis, arterial hypertension remained a statistically significant predictor of survival benefit (p<0.001) regardless of how it was defined and of potential confounding influences.
This phenomenon had not been observed in GIST patients in routine practice outside clinical trials until our recent report. 17 In our study, it proved to be an independent factor influencing both PFS and OS (see Figures 2 and 3 ).
In the clinical setting, there is a wide heterogeneity in therapeutic efficacy and degree of toxicity experienced by patients treated with
TKIs, which may eventually be linked to a genetic background influencing an individual patient's susceptibility. Arterial hypertension caused by TKIs has been shown to be dependent on the potency of these inhibitors against VEGFR2. 57 In exploring individual susceptibility, genetic variations -specifically single nucleotide polymorphisms (SNPs) that reside in coding and non-coding regions within VEGF and VEGFR2 -have shown potential as biomarkers of clinical response to, and/or toxicity of, VEGF pathway-targeted therapy. [58] [59] [60] [61] [62] [63] Among RCC patients, after adjustment for pre-treatment arterial hypertension and use of antihypertensive drugs, patients with less favourable VEGF genotypes were estimated to have a 13 to 14 times greater likelihood of being hypertensive during treatment, compared with patients with the more favourable genotypes. On the other hand, none of the VEGFR2 SNPs analysed were associated with the prevalence of arterial hypertension. 60 That study found no association between SNPs and outcomes, and the correlation between arterial hypertension and therapy outcomes was not explored. In another, more systematic search for a genetic background indicative of a prolonged PFS and/or OS, among 11 genes studied in 136 patients, genetic variants in the CYP3A5, NR1I3 and ABCB1 genes were predictive factors of prolonged PFS.
In addition, a role for an allele of VEGFR2 in prolonged OS as a secondary outcome was found. 64 In a subgroup of 39 patients that we analysed, a trend for a possible pharmacogenetic relationship with sunitinib tolerance emerged. 
